Jpmorgan Chase & Co »

Sonnet Biotherapeutc Hldng I shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Sonnet Biotherapeutc Hldng I (SONN) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Sonnet Biotherapeutc Hldng I

Tip: Access up to 7 years of quarterly data

All positions including Sonnet Biotherapeutc Hldng I held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sonnet Biotherapeutc Hldng I by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2023-12-31 $32 19 1.74

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Trust Fund (SPY)
Nvidia Corporation Common (NVDA)
Meta Platforms Common (META)
Unitedhealth Group Common (UNH)
Vanguard Total Intl Bond Etf Fund (BNDX)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Mastercard Incorporated Common (MA)
Alphabet Common (GOOGL)
Abbvie Common (ABBV)
Vanguard Total Bond Market Fund (BND)
Tesla Common (TSLA)

View all positions for Jpmorgan Chase & Co

Top funds holding Sonnet Biotherapeutc Hldng I

Citadel Advisors
Vanguard Group
Advisor Group Holdings
Wells Fargo & Company
Jpmorgan Chase & Co
Private Wealth Management Group

View all funds holding Sonnet Biotherapeutc Hldng I